含利奈唑胺的联合用药方案治疗耐多药结核病患者的效果分析

Effect Analysis of the Combination of Linezolid in the Treatment of Patients with Multidrug-resistant Tuberculosis

目的分析含利奈唑胺的联合用药方案对耐多药肺结核患者进行治疗的临床效果。方法将2018年3月至2019年3月到我院治疗的82例耐多药肺结核患者随机分为观察组与对照组,每组各41例。两组患者均通过常规基础治疗进行干预,对照组在常规治疗基础上配合左氧氟沙星治疗,而观察组在对照组的基础上使用利奈唑胺(含利奈唑胺的联合用药疗法)进行治疗,比较两组的治疗效果。结果观察组的治疗总有效率为97.56%(40/41),对照组为78.05%(32/41),P<0.05,差异具有统计学意义;观察组不良反应发生率为7.32%(3/41),其中存在肝肾功能损伤、末梢神经炎和胃肠道不适患者各1例,对照组为4.88%(2/41),其中存在肝肾功能损伤患者1例,胃肠道不适患者1例,P>0.05,差异不存在统计学意义。结论对耐多药肺结核患者治疗时通过含利奈唑胺的联合用药方案可有效提高患者的治疗总有效率,降低不良反应对患者的影响,帮助患者进行临床症状的控制和改善,值得推广。

Objective To analyze the clinical effect of linezolid combined with a combination regimen in the treatment of patients with multidrug-resistant tuberculosis.Methods From March 2018 to March 2019,82 patients with multi-drug resistant pulmonary tuberculosis who came to our hospital for treatment were randomly divided into observation group and control group,with the same number of 41 cases.The two groups of patients were intervened by conventional basic treatment.The control group was treated with levofloxacin on the basis of conventional treatment,while the observation group was treated with linezolid(combination therapy containing linezolid)on the basis of the control group,and the effects were compared.Results The total effective rate of the observation group was 97.56%(40/41),and that of the control group was 78.05%(32/41),P<0.05,the difference was statistically significant.The incidence of adverse reactions in the observation group was 7.32%(3/41),there were 1 case each with liver and kidney function damage,peripheral neuritis and gastrointestinal discomfort,and the incidence of adverse reactions in the control group was 4.88%(2/41),including 1 case of liver and kidney dysfunction and 1 case of gastrointestinal discomfort,P>0.05,the difference was not statistically significant.Conclusion The combination of linezolid in the treatment of multidrug-resistant tuberculosis patients can effectively improve the total effective rate of treatment,reduce the impact of adverse reactions on patients,and help patients to control and improve clinical symptoms,which is worth promoting.